Journal: bioRxiv
Article Title: Uncovering cancer dependencies in peptide-interacting protein pockets
doi: 10.64898/2026.03.13.711608
Figure Lengend Snippet: ( A ) Scheme showing how an overexpressed motif peptide from protein Y could outcompete the endogenous interaction between proteins X and Y and other interactions involving that pocket on protein X. ( B ) MDM2 SWIB domain binds to a degron motif in p53, leading to p53 degradation and maintenance of low p53 expression. ( C ) Superimposed structures of MDM2 SWIB domain in complex with the p53 degron peptide and Nutlin-3a. ( D ) Western blot images showing the dose-response of HCT116 cells to Nutlin-3a and p53 degron competitor peptides. ( E ) Flow cytometry plots showing the change in GFP-positive and mCherry-positive cell fractions in a pairwise competitive growth experiment in HCT116 cells. ( F ) Fusion with NLS and NES motifs localises the competitor peptides to different subcellular compartments, which impacts the anti-proliferative effect of the p53 peptide, as observed in a pairwise GFP/mCherry cell competitive growth experiment in HCT116. ( G ) Pairwise competitive growth experiments showing the impact of motif repeats on the potency of competitors based on NUMB MDM2 degron in HCT116. ( H ) Experimental scheme of proteome-wide competitor peptide screening to identify peptide-binding pocket inhibition vulnerabilities. ( I ) The distribution of peptide abundance changes in 9 cancer cell lines. The error bars show 5-95% percentile. ( J ) Heatmap showing dropout scores (log2 fold change) of the peptides identified as anti-proliferative in at least 7 cell lines.
Article Snippet: The following primary antibodies were used: ab13970 chicken polyclonal to GFP at 1:5000, p21 (12D1) Rabbit mAb (#2947, Cell Signaling Technologies) at 1:1000, p53 (1C12) Mouse mAb (#2524, Cell Signaling Technology) at 1:500, Hcfc1 Antibody (Amino-terminal Antigen) (#69690, Cell Signaling Technology) at 1:1000, TLE1 (F-4) (sc-137098, Santa Cruz Biotechnologies) at 1:500, TLE2 (D-10) (sc-374226, Santa Cruz Biotechnologies) at 1:500, TLE3 (D-10) (sc-514798, Santa Cruz Biotechnologies) at 1:500, TLE4 (E-10) (sc-365406, Santa Cruz Biotechnologies) at 1:500, TLE1/2/3/4 (#4681, Cell Signaling Technologies) at 1:500, ATF4 (PA5-27576, Thermo Fisher Scientific) at 1:2000, DDIT3 (R-20) (sc-793, Santa Cruz Biotechnologies) at 1:500, Vinculin (#13901, Cell Signaling Technology) at 1:1000, DHPS (A-10) (sc-365077, Santa Cruz Biotechnologies) at 1:500, ACOX3 (17360-1-AP, Proteintech) at 1:500, cyclin D1 (sc-20044, Santa Cruz Biotechnologies) at 1:500, cyclin D2 (D52F9) (#3741, Cell Signaling Technology) at 1:1000, cyclin D3 (DCS22) (#2936, Cell Signaling Technology) at 1:1000, eIF5A (D8L8Q) (#20765, Cell Signaling Technology) at 1:1000, hypusine (ABS1064-I, EMD Millipore) at 1:1000.
Techniques: Expressing, Western Blot, Flow Cytometry, Binding Assay, Inhibition